logo
Share SHARE
FONT-SIZE Plus   Neg

Telik Says FDA Grants Orphan Drug Status To Telintra, Shares Soar - Quick Facts

Telik, Inc. (TELK) announced that its product candidate, ezatiostat HCL (Telintra), has been granted orphan drug designation by the US Food and Drug Administration for the treatment of myelodysplastic syndrome (MDS).

Orphan designation grants potential US market exclusivity to a drug for the treatment of a specified condition for a period of seven years following FDA marketing approval.

Telintra is a novel inhibitor of the enzyme glutathione S-transferase P1-1, leading to activation of Jun kinase, a key regulator of cellular growth and differentiation of blood precursor cells.

Telintra has been shown to cause clinically significant and sustained reduction in red blood cell transfusions, transfusion independence and multilineage responses in MDS patients. The results of four clinical trials of Telintra in MDS have been reported in peer-reviewed scientific journals.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Canada's banking regulator has released tougher mortgage-financing rules for borrowers in the uninsured segment of the mortgage market, which has been responsible for the major share of growth recently. It includes a requirement to "stress test" borrowers with uninsured loans to ensure they can withstand the impact of higher interest rates. McDonald's offers smartphone lockers so as to help customers spend quality time during family meals. The "Phone off. Fun On" campaign, introduced recently in a Singapore branch, aims to encourage diners to take a break from the virtual world to have real conversations over meals. U.S. Bancorp (USB) reported net income of $1.56 billion for the third quarter of 2017, or $0.88 per share, compared to $1.50 billion, or $0.84 per share, in the third quarter of 2016. On average, 28 analysts polled by Thomson Reuters expected the company to report profit per share of $0.88 for the quarter....
comments powered by Disqus
Follow RTT